Excelsior Biopharma Inc. (TPEX:6496)
Taiwan
· Delayed Price · Currency is TWD 26.20
-0.85 (-3.14%)
At close: Mar 9, 2026
Excelsior Biopharma Revenue
In the year 2025, Excelsior Biopharma had annual revenue of 898.26M TWD with 4.22% growth. Excelsior Biopharma had revenue of 279.22M in the quarter ending December 31, 2025, with 15.99% growth.
Revenue
898.26M
Revenue Growth
+4.22%
P/S Ratio
1.36
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.22B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 898.26M | 36.35M | 4.22% |
| Dec 31, 2024 | 861.91M | 90.35M | 11.71% |
| Dec 31, 2023 | 771.56M | 99.80M | 14.86% |
| Dec 31, 2022 | 671.76M | -666.63M | -49.81% |
| Dec 31, 2021 | 1.34B | -105.27M | -7.29% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| DV Biomed | 712.61M |
| Anxo Pharmaceutical | 883.22M |
| Original BioMedicals | 381.00K |
| Winston Medical Supply | 724.35M |
| Mediera | 229.85M |
| Prince Pharmaceutical | 798.27M |
| InnoPharmax | 55.77M |
| Tien Liang BioTech | 467.02M |